urban
human
migrat
climat
chang
facilit
emerg
reemerg
larg
number
virus
caus
unexpect
ill
epidem
capac
identifi
control
emerg
diseas
limit
poorer
region
mani
origin
among
emerg
reemerg
virus
member
flavivirida
famili
repres
global
public
health
issu
flavivirida
famili
consist
four
genera
flaviviru
hepaciviru
pegiviru
pestiviru
includ
virus
respons
import
anim
human
diseas
yellow
fever
viru
yfv
zika
viru
zikv
japanes
enceph
viru
jev
west
nile
viru
wnv
hepat
c
viru
hcv
dengu
viru
denv
yfv
zikv
jev
wnv
denv
lead
caus
arthropodborn
human
diseas
worldwid
accord
world
health
organ
global
infect
million
individu
year
caus
approxim
death
year
hcv
bloodborn
hepaciviru
respons
chronic
liver
diseas
caus
approxim
death
annual
approxim
million
individu
infect
worldwid
repres
global
popul
recent
approv
larg
number
directact
antivir
agent
daa
activ
hcv
includ
gener
compound
revolution
treatment
infect
rate
infect
cure
contrast
antivir
drug
avail
far
cure
infect
caus
arthropodborn
member
flavivirida
famili
despit
global
public
health
import
past
year
two
differ
type
antivir
agent
includ
daa
hosttarget
antivir
hta
agent
develop
treatment
hcv
infect
among
hta
nonimmunosuppress
deriv
cyclosporin
csa
target
host
cyclophilin
cyp
yield
promis
result
alisporivir
alv
first
hta
enter
hcv
clinic
develop
reach
phase
iii
clinic
trial
develop
halt
follow
report
seven
case
acut
pancreat
includ
lethal
one
event
independ
cyp
inhibit
like
due
alvinduc
hypertriglyceridemia
potenti
pancreat
toxic
interferon
alpha
part
combin
regimen
although
cyclophilin
inhibitor
cypi
fail
reach
market
indic
hepat
c
treatment
remain
attract
combat
viral
infect
inde
cypi
report
involv
life
cycl
virus
hcv
high
barrier
resist
broad
antivir
activ
possibl
addit
synergist
effect
antivir
compound
variou
model
cyp
peptidylprolyl
cistran
isomeras
ppias
catalyz
interconvers
two
energet
prefer
conform
ci
tran
planar
peptid
bond
preced
intern
prolin
residu
seventeen
human
cyp
identifi
may
exist
cyp
convincingli
shown
play
pivot
role
life
cycl
larg
number
virus
differ
famili
howev
data
avail
regard
antiflavivirida
activ
cypi
obtain
csa
alv
molecular
mechan
antihcv
activ
cypi
yet
fulli
understood
believ
exert
antivir
effect
disrupt
cypanonstructur
protein
interact
regul
multipl
phase
hcv
replic
previous
report
ration
design
new
famili
smallmolecul
nonpeptid
cypi
smcypi
unrel
csa
mean
complex
fragmentbas
drug
discoveri
approach
smcypi
display
antivir
effect
hcv
also
hiv
coronavirus
suggest
togeth
data
report
literatur
could
act
broadspectrum
antivir
agent
effect
number
differ
virus
differ
viru
famili
present
studi
aim
character
antihcv
activ
new
famili
smcypi
unravel
molecular
antivir
mechan
evalu
spectrum
antiflavivirida
activ
work
present
oral
commun
intern
symposium
hepat
c
viru
relat
virus
kyoto
japan
octob
antihcv
activ
new
smcypi
compound
potent
inhibitor
cyp
ppias
activ
test
differ
hcv
genotyp
model
contain
luciferas
report
gene
includ
infecti
chimer
genotyp
viru
genotyp
hcv
subgenom
replicon
hcvsgr
chimer
hcvsgr
contain
genotyp
sequenc
see
fig
supplement
materi
addit
antihcv
activ
evalu
recent
develop
fulllength
infecti
hcv
genotyp
model
alv
csa
use
control
experi
equal
inhibit
replic
genotyp
hcvsgr
chimer
genotyp
hcvsgr
effect
concentr
rang
tabl
also
inhibit
replic
infecti
viru
compar
final
inhibit
rna
replic
dosedepend
manner
maxim
hcv
rna
reduct
fig
affect
cell
viabil
effect
concentr
fig
altogeth
result
demonstr
pangenotyp
activ
new
smcypi
understand
molecular
mechan
antihcv
action
new
smcypi
cypa
bind
mode
csa
model
fig
b
respect
shown
fig
structur
cypa
complex
reveal
expect
dual
bind
hydrophob
pocket
cypa
ppias
activ
site
one
hand
gatekeep
pocket
hand
interestingli
methoxi
group
compound
push
creat
hydrogen
bond
urea
moieti
compound
cypa
bind
site
csa
partial
overlap
suggest
competit
bind
cypa
thu
timeresolv
fluoresc
reson
energi
transfer
trfret
use
assess
whether
compet
csa
bind
purifi
cypa
nonlabel
csa
alv
displac
label
csa
cypa
bind
site
kd
dissoci
constant
valu
nm
respect
data
shown
shown
fig
also
displac
label
csa
kd
valu
nm
confirm
competit
csa
bind
cypa
final
assess
whether
antihcv
effect
smcypi
relat
abil
inhibit
cypa
ppias
enzym
activ
antihcv
activ
differ
chemic
relat
smcypi
list
tabl
supplement
materi
includ
determin
genotyp
hcvsgr
plot
respect
inhibitori
activ
ppias
enzym
assay
shown
fig
antihcv
activ
smcypi
strongli
correl
abil
inhibit
ppias
activ
pearson
correl
coeffici
p
valu
altogeth
result
demonstr
new
famili
smcypi
inhibit
hcv
replic
bind
ppias
catalyt
pocket
gatekeep
pocket
cypa
thu
block
ppias
catalyt
activ
cypa
shown
play
import
role
hcv
life
cycl
interact
protein
measur
effect
interact
purifi
cypa
tag
polyhistidin
sequenc
bound
ninta
nitrilotriacet
acid
magnet
bead
cell
lysat
contain
wildtyp
mutant
fuse
renilla
luciferas
incub
cypaload
magnet
bead
presenc
absenc
alv
use
control
wash
elut
imidazol
luciferas
activ
correspond
interact
complex
measur
shown
fig
interact
disrupt
alv
dosedepend
manner
result
observ
togeth
result
indic
smcypi
disrupt
interact
cypa
hcv
protein
bind
cypa
studi
combin
inhibitor
ledipasvir
ldv
perform
cell
stabli
harbor
genotyp
hcvsgr
shown
fig
select
pressur
combin
ldv
respect
pm
effect
cure
cell
replicon
compound
alon
concentr
suggest
least
addit
effect
ldv
combin
addit
genotyp
hcvsgr
contain
substitut
confer
highlevel
resist
ledipasvir
increas
ldv
data
shown
remain
fulli
sensit
alv
tabl
togeth
result
suggest
new
smcypi
famili
least
addit
effect
hcv
daa
target
domain
protein
without
crossresist
cell
stabli
harbor
genotyp
hcvsgr
contain
neomycin
resist
gene
grown
select
pressur
absenc
presenc
increas
dose
two
cellular
clone
grow
presenc
select
day
csa
nonimmunosuppress
deriv
shown
select
amino
acid
substitut
region
hcv
genom
region
two
clone
sequenc
compar
baselin
amino
acid
chang
identifi
includ
domain
domain
ii
domain
iii
protein
fig
region
also
sequenc
chang
observ
data
shown
amino
acid
substitut
select
introduc
wt
transient
genotyp
hcvsgr
phenotyp
analysi
compound
suscept
replic
capac
presenc
alv
csa
tabl
among
mutat
associ
mild
increas
without
impair
replicon
replic
capac
locat
domain
drastic
reduc
correspond
hcvsgr
replic
capac
impact
compound
suscept
could
evalu
thu
domain
ii
protein
select
serial
passag
increas
concentr
confer
lowlevel
resist
smcypi
describ
csa
alv
assess
whether
could
exert
antivir
activ
member
flavivirida
famili
viral
replic
assess
revers
transcriptionquantit
pcr
rtqpcr
h
postinfect
dosedepend
decreas
viral
replic
observ
presenc
denv
yfv
zikv
cytotox
concentr
fig
potent
hcv
denv
yfv
zikv
although
potent
flavivirida
hcv
compound
repres
good
candid
chemic
optim
antihcv
drug
research
highlight
antivir
potenti
cyp
inhibit
clinic
develop
nonimmunosuppress
deriv
csa
unfortun
cypi
develop
hcv
structur
relat
compound
reach
latephas
clinic
develop
alv
halt
due
sever
advers
effect
unrel
cyp
inhibit
recent
report
use
complex
fragmentbas
drug
discoveri
approach
use
nucleic
magnet
reson
xray
crystallographi
structurebas
compound
optim
gener
new
famili
nonpeptid
smallmolecul
cyclophilin
inhibitor
smcypi
unrel
csa
broad
cyclophilin
vitro
ppiaseinhibitori
activ
antivir
activ
hcv
hiv
coronavirus
although
alv
shown
potent
inhibit
hcv
replic
abil
block
replic
member
flavivirida
famili
unknown
immunosuppress
agent
csa
report
bear
antivir
activ
wnv
yfv
less
potenc
wnv
result
regard
suscept
zikv
csa
limit
contradictori
spars
data
prompt
us
assess
antiflavivirida
activ
new
smcypi
show
smcypi
inhibitor
ppias
activ
antihcv
activ
vitro
also
inhibit
replic
sever
member
flavivirida
famili
cell
cultur
model
effect
hcv
denv
replic
lowmicromolar
rang
inhibit
yfv
zikv
replic
lesser
extent
micromolar
rang
although
highest
concentr
test
trend
toward
decreas
viral
replic
also
observ
wnv
data
shown
contrast
effect
jev
replic
observ
experi
data
shown
knowledg
first
smcypi
potenti
broad
antiflavivirida
activ
given
chemic
plastic
simplic
synthesi
new
famili
smcypi
larg
number
new
compound
synthes
futur
thu
like
deriv
greater
effect
differ
member
flavivirida
famili
gener
suscept
flavivirida
famili
member
smcypi
suggest
cyclophilin
play
pivot
role
life
cycl
howev
differ
antivir
potenc
across
differ
virus
flavivirida
famili
rais
question
whether
similar
differ
mechan
inhibit
smcypi
provid
uniqu
easytous
tool
explor
role
present
studi
use
deciph
role
cyclophilin
hcv
life
cycl
understand
mechan
inhibit
inhibitor
result
complement
previou
result
gener
csa
alv
variou
model
show
like
alv
famili
smcypi
pangenotyp
antihcv
activ
lowmicromolar
rang
genotyp
high
barrier
select
resist
virus
least
addit
effect
combin
hcv
daa
demonstr
previous
cypa
ppias
activ
requir
hcv
replic
librari
smcypi
see
tabl
supplement
materi
provid
us
uniqu
thusfarmiss
pharmacolog
tool
dissect
molecular
mechan
cypviru
interact
antivir
effect
cyp
inhibit
librari
smcypi
prove
particularli
use
discrimin
ppiasedepend
antivir
activ
effect
relat
function
role
cyp
use
sever
smcypi
deriv
differ
potenc
inhibit
ppias
catalyt
activ
show
antivir
activ
smcypi
strongli
correl
ppiaseinhibitori
potenc
confirm
cyp
ppias
activ
requir
hcv
replic
shown
previous
cypa
interact
directli
hcv
protein
regul
key
process
hcv
life
cycl
disrupt
key
interact
csa
alv
impair
hcv
replic
possibl
explain
antihcv
effect
compound
whether
similar
mechan
could
involv
famili
cyp
inhibitor
remain
unknown
show
interact
disrupt
also
model
cypa
bind
mode
csa
expect
superimposit
suggest
compound
share
partial
overlap
bind
site
result
confirm
mean
trfret
assay
show
displac
csa
cypa
catalyt
site
interestingli
also
observ
anilin
moieti
deepli
buri
pocket
contigu
canon
catalyt
site
gatekeep
pocket
reach
csa
suggest
mode
inhibit
csa
smcypi
may
partial
differ
could
explain
csa
alv
inhibit
zikv
replic
studi
wherea
possibl
ppiaseindepend
mechan
differ
involv
hcv
inhibit
data
shown
resist
experi
perform
alv
csa
select
amino
acid
substitut
essenti
cluster
domain
ii
hcv
protein
also
suggest
main
viral
partner
cypa
mutat
locat
domain
ii
report
confer
lowlevel
resist
csa
nonimmunosuppress
deriv
howev
mutant
protein
harbor
substitut
keep
capac
interact
cypa
vitro
interact
remain
fulli
sensit
alv
disrupt
experi
day
necessari
select
two
cellular
clone
grow
presenc
select
pressur
maximum
select
pressur
obtain
keep
data
report
previous
alv
csa
respect
result
confirm
high
barrier
resist
smcypi
among
amino
acid
chang
identifi
clone
domain
ii
protein
associ
modest
increas
without
impair
replicon
replic
capac
interact
cypa
remain
fulli
sensit
disrupt
altogeth
find
confirm
mode
antivir
action
smcypi
ident
csa
deriv
fact
smcypi
target
viral
function
instead
target
host
protein
involv
key
step
viru
life
cycl
suggest
could
bear
addit
synergist
properti
combin
daa
confirm
hypothesi
combin
potent
hcv
inhibitor
ledipasvir
drug
togeth
effici
cure
cell
hcvsgr
drug
alon
suggest
least
addit
effect
addit
remain
effici
hcvsgr
harbor
amino
acid
substitut
known
confer
highlevel
resist
ldv
conclus
new
famili
smcypi
presum
exhibit
broadspectrum
antivir
properti
sever
member
flavivirida
famili
repres
import
public
health
problem
worldwid
remain
without
therapeut
option
mechan
antivir
action
one
virus
hcv
relat
cyp
bind
inhibit
ppias
catalyt
activ
disrupt
interact
mechan
common
cyclophilin
inhibitor
deriv
csa
nonimmunosuppress
analogu
csa
suffer
seriou
caveat
includ
larg
size
result
poor
cell
permeabl
side
effect
unrel
cyclophilin
inhibit
drugdrug
interact
manufactur
issu
thu
chemic
plastic
low
cellular
toxic
simplic
synthesi
new
famili
smcypi
repres
promis
new
class
drug
broadspectrum
antiflavivirida
properti
well
invalu
tool
explor
role
cyclophilin
viru
life
cycl
mechan
block
alisporivir
alv
ledipasvir
ldv
purchas
agv
discoveri
clapier
franc
cyclosporin
csa
purchas
sigmaaldrich
st
loui
mo
usa
smcypi
compound
synthesi
describ
text
supplement
materi
chemic
reagent
obtain
aldrich
chemic
st
loui
mo
usa
acro
organ
geel
belgium
abcr
gmbh
karlsruh
germani
acbblock
toronto
canada
chembridg
san
diego
ca
use
without
purif
plasmid
contain
firefli
luciferas
report
gene
genotyp
hcv
subgenom
respect
kindli
provid
charl
rice
rockefel
univers
new
york
ny
plasmid
ni
contain
firefli
luciferas
report
gene
genotyp
hcv
subgenom
strain
cassett
genotyp
hcvn
strain
plasmid
contain
renilla
luciferas
report
gene
genotyp
hcv
subgenom
respect
purchas
apath
llc
new
york
ny
usa
plasmid
contain
neomycin
resist
gene
hcv
genotyp
subgenom
use
resist
select
experi
kindli
provid
ralf
bartenschlag
univers
heidelberg
heidelberg
germani
plasmid
contain
fulllength
hcv
genotyp
genom
kindli
provid
jen
bukh
univers
copenhagen
copenhagen
denmark
final
chimer
plasmid
consist
genotyp
sequenc
insert
genotyp
hcv
subgenom
develop
laboratori
human
hepatoma
cell
kindli
provid
elian
meur
cell
apath
llc
cultur
complet
dulbecco
modifi
eagl
medium
dmem
thermo
fisher
scientif
waltham
usa
supplement
fetal
bovin
serum
iuml
penicillin
streptomycin
amphotericin
b
thermo
fisher
scientif
transient
hcvsgr
model
plasmid
ni
linear
xhoi
xbai
xbai
respect
fastdigest
thermo
fisher
scientif
vitro
transcrib
use
megascript
transcript
kit
thermo
fisher
scientif
next
approxim
cell
transfect
ng
hcvsgr
rna
use
transit
mrna
transfect
kit
miru
bio
llc
madison
wi
usa
four
hour
transfect
compound
ad
cultur
medium
luciferas
activ
monitor
h
posttransfect
genotyp
genotyp
chimer
genotyp
hcvsgr
respect
cell
stabli
harbor
genotyp
hcvsgr
cultur
presenc
compound
h
luciferas
activ
measur
plot
fit
fourparamet
logist
curv
sigmaplot
softwar
systat
softwar
inc
determin
curv
cell
seed
densiti
cell
incub
h
infect
cellculturederiv
infecti
hcv
hcvcc
strain
genotyp
presenc
increas
concentr
compound
eight
hour
infect
cell
wash
phosphatebuff
salin
pb
incub
fresh
medium
contain
inhibitor
h
luciferas
activ
measur
plot
compound
concentr
determin
curv
fit
fourparamet
logist
equat
cell
stabli
harbor
genotyp
hcvsgr
cultur
presenc
pm
ldv
drug
concentr
absenc
presenc
passag
remain
live
cell
stain
crystal
violet
cell
stabli
harbor
genotyp
hcvsgr
replicon
confer
cell
resist
use
select
experi
cell
cultur
presenc
escal
dose
mgml
coloni
grow
presenc
appear
two
resist
coloni
isol
sever
passag
total
rna
extract
rneasi
minikit
qiagen
hilden
germani
revers
transcrib
highcapac
cdna
revers
transcript
kit
thermo
fisher
scientif
region
amplifi
baselin
resist
coloni
pcr
use
forward
oligonucleotid
cag
tgg
atg
aay
cgg
ctg
ata
car
gac
tct
arc
art
atg
tgc
ctg
aga
gcg
ttg
tar
tcc
gg
cgi
gcc
cat
revers
oligonucleotid
crt
gyg
agc
cyg
aac
gtg
acg
cag
caa
aga
aca
tta
cag
cag
aga
cgg
atg
ggc
agc
ttg
candid
resistanceassoci
substitut
rass
introduc
wildtyp
genotyp
hcvsgr
contain
luciferas
report
gene
mean
sitedirect
mutagenesi
quikchang
ii
xl
sitedirect
mutagenesi
kit
agil
technolog
santa
clara
ca
usa
ninetysix
hour
rna
transfect
suscept
rascontain
hcvsgr
compound
determin
measur
luciferas
activ
comparison
wildtyp
hcvsgr
suscept
replic
capac
rascontain
hcvsgr
assess
compar
luciferas
activ
h
h
posttransfect
express
percentag
wildtyp
replic
capac
rass
confer
highlevel
resist
ldv
introduc
region
plasmid
mean
sitedirect
mutagenesi
linear
scai
vitro
transcript
genotyp
hcvsgr
transfect
cell
cell
cultur
presenc
compound
h
luciferas
activ
measur
suscept
hcvsgr
alv
ldv
compar
wildtyp
hcvsgr
trfret
timeresolv
fluoresc
energi
transfer
assay
selcia
ongar
uk
use
determin
competit
cypa
bind
csa
briefli
cypa
tag
polyhistidin
sequenc
form
complex
antibodi
label
fluoresc
donor
f
csa
tag
fluoresc
acceptor
f
ad
master
mix
contain
cypaantibodycsa
complex
final
concentr
deterg
min
incub
room
temperatur
plate
read
spectramax
instrument
molecular
devic
sunnyval
ca
usa
wavelength
detect
f
f
emiss
f
f
ratio
calcul
valu
plot
inhibitor
concentr
molar
fit
use
onesit
ki
nonlinear
regress
determin
kd
nonlabel
csa
alv
use
control
vitro
interact
assay
develop
measur
effici
cypi
disrupt
interact
luminesc
measur
pcr
amplif
primer
aac
tgc
aga
tgt
ccg
gct
cgt
ggc
aac
cgc
ggg
cag
cag
acg
acg
digest
psti
sacii
fastdigest
thermo
fischer
scientif
genotyp
sequenc
clone
fusion
renilla
luciferas
h
plasmid
catalogu
number
perkinelm
waltham
usa
gener
sitedirect
mutagenesi
oligonucleotid
ggc
acg
ccc
gga
ata
caa
ccc
tcc
act
tgg
agg
gtt
gta
ttc
cgg
gcg
tgc
cca
clone
similarli
cell
transfect
plasmid
fortyeight
hour
later
cell
lyse
thawfreez
cycl
incub
min
room
temperatur
ninta
magnet
bead
preload
purifi
cypa
equilibr
buffer
mm
imidazol
tween
pb
increas
concentr
cypi
ad
incub
bead
wash
time
wash
buffer
mm
imidazol
tween
pb
elut
perform
mm
imidazol
min
room
temperatur
renilla
luciferas
activ
eluat
measur
renilla
luciferas
assay
system
promega
result
present
mean
standard
deviat
sd
data
least
three
independ
experi
analys
two
side
consid
signific
p
valu
molecular
model
dock
experi
perform
use
server
integr
origin
interfac
compar
dock
small
molecul
detect
protein
data
bank
pdb
file
templat
search
homolog
sequenc
align
perform
use
server
cypd
sequenc
ncbi
access
number
ident
structur
model
activesit
boundari
deduc
vicin
cocrystal
ligand
compound
select
templat
pdb
access
number
respect
use
compar
option
addit
chemic
entiti
use
defin
shape
restraint
guid
dock
automat
comput
model
file
ligand
gener
marvinsketch
smile
server
figur
b
gener
use
pymol
cell
infect
h
yfv
strain
dakar
hd
obtain
world
refer
center
emerg
virus
arbovirus
wrceva
tx
usa
multipl
infect
moi
h
strain
dominica
obtain
centro
de
cuba
moi
h
zikv
strain
obtain
atcc
moi
infect
perform
presenc
differ
concentr
denv
yfv
experi
total
rna
extract
cell
cultur
nucleospin
rna
ii
kit
machereynagel
firststrand
cdna
synthesi
perform
revertaid
h
minu
moloney
murin
leukemia
viru
mmulv
revers
transcriptas
quantit
realtim
pcr
perform
realtim
pcr
system
quantstudio
flex
appli
biosystem
sybr
green
pcr
master
mix
life
technolog
data
analyz
method
valu
sampl
normal
valu
dehydrogenas
gapdh
experi
perform
triplic
genomeequival
concentr
determin
extrapol
standard
curv
gener
serial
dilut
plasmid
encod
subgenom
yfv
replicon
sequenc
primer
use
rtqpcr
follow
sens
antisens
sequenc
pandenv
primer
follow
sens
antisens
zikv
experi
total
rna
extract
cell
cultur
total
rna
isol
system
promega
revers
transcript
perform
highcapac
cdna
revers
transcript
kit
appli
biosystem
quantit
realtim
pcr
perform
realtim
pcr
system
appli
biosystem
system
taqman
gene
express
master
mix
appli
biosystem
data
normal
valu
gapdh
sequenc
primer
use
follow
sens
antisens
statist
analys
perform
use
sigmaplot
softwar
statist
calcul
use
test
analysi
varianc
p
valu
consid
statist
signific
